SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-22-003588
Filing Date
2022-05-13
Accepted
2022-05-13 17:01:25
Documents
37
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cns_i10q-033122.htm   iXBRL 10-Q 364760
2 CERTIFICATION cns_ex3101.htm EX-31.1 7020
3 CERTIFICATION cns_ex3102.htm EX-31.2 6835
4 CERTIFICATION cns_ex3201.htm EX-32.1 3108
5 CERTIFICATION cns_ex3202.htm EX-32.2 3260
  Complete submission text file 0001683168-22-003588.txt   2172398

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20220331.xsd EX-101.SCH 19403
7 XBRL CALCULATION FILE cnsp-20220331_cal.xml EX-101.CAL 24340
8 XBRL DEFINITION FILE cnsp-20220331_def.xml EX-101.DEF 83630
9 XBRL LABEL FILE cnsp-20220331_lab.xml EX-101.LAB 193779
10 XBRL PRESENTATION FILE cnsp-20220331_pre.xml EX-101.PRE 145959
31 EXTRACTED XBRL INSTANCE DOCUMENT cns_i10q-033122_htm.xml XML 190333
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 22923764
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences